Aratana Therapeutics Inc. (NASDAQ:PETX)’s share price traded down 0.8% on Wednesday following insider selling activity. The stock traded as low as $9.82 and last traded at $10.22, with a volume of 766,019 shares trading hands. The stock had previously closed at $10.30.
Specifically, insider Peter Steven St sold 50,000 shares of the stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $9.25, for a total transaction of $462,500.00. Following the completion of the transaction, the insider now owns 642,793 shares in the company, valued at $5,945,835.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Craig A. Tooman sold 30,000 shares of the stock in a transaction on Friday, September 9th. The shares were sold at an average price of $9.25, for a total transaction of $277,500.00. Following the transaction, the insider now owns 72,424 shares of the company’s stock, valued at approximately $669,922. The disclosure for this sale can be found here. Company insiders own 6.70% of the company’s stock.
Several equities analysts have commented on the stock. Barclays PLC lowered their price objective on shares of Aratana Therapeutics from $15.00 to $11.00 and set an “overweight” rating for the company in a research report on Thursday, August 11th. Jefferies Group assumed coverage on shares of Aratana Therapeutics in a research report on Friday, August 19th. They set a “buy” rating and a $13.00 price objective for the company. Zacks Investment Research lowered shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, July 28th. William Blair restated an “outperform” rating on shares of Aratana Therapeutics in a report on Wednesday, August 17th. Finally, Lake Street Capital restated a “buy” rating and issued a $15.00 target price on shares of Aratana Therapeutics in a report on Tuesday, September 6th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $11.28.
The firm’s 50 day moving average price is $9.24 and its 200 day moving average price is $7.30. The company’s market capitalization is $355.57 million.
Aratana Therapeutics (NASDAQ:PETX) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.24 by $0.37. The company earned $38.05 million during the quarter, compared to analyst estimates of $15.14 million. Aratana Therapeutics had a negative net margin of 166.67% and a negative return on equity of 17.53%. During the same quarter in the previous year, the firm earned ($0.23) EPS. Equities research analysts forecast that Aratana Therapeutics Inc. will post ($0.77) earnings per share for the current fiscal year.
Several large investors have recently added to or reduced their stakes in the company. Metropolitan Life Insurance Co. NY acquired a new stake in Aratana Therapeutics during the second quarter worth about $162,000. First Light Asset Management LLC raised its stake in Aratana Therapeutics by 52.9% in the second quarter. First Light Asset Management LLC now owns 684,921 shares of the biopharmaceutical company’s stock worth $4,329,000 after buying an additional 236,915 shares during the last quarter. A.R.T. Advisors LLC raised its stake in Aratana Therapeutics by 81.5% in the second quarter. A.R.T. Advisors LLC now owns 71,515 shares of the biopharmaceutical company’s stock worth $451,000 after buying an additional 32,111 shares during the last quarter. Bridgeway Capital Management Inc. raised its stake in Aratana Therapeutics by 85.1% in the second quarter. Bridgeway Capital Management Inc. now owns 86,983 shares of the biopharmaceutical company’s stock worth $550,000 after buying an additional 40,000 shares during the last quarter. Finally, Parametric Portfolio Associates LLC raised its stake in Aratana Therapeutics by 16.6% in the second quarter. Parametric Portfolio Associates LLC now owns 27,958 shares of the biopharmaceutical company’s stock worth $177,000 after buying an additional 3,989 shares during the last quarter. 85.56% of the stock is owned by institutional investors and hedge funds.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.